PET/CT imaging of I-124-radiolabeled bevacizumab and ranibizumab after intravitreal injection in a rabbit model

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 8, 2011, Pages 5899-5903

  Christoforidis, John B ^a   Carlton, Michelle M ^a   Knopp, Michael V ^a   Hinkle, George H ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; IODINE 124; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE;

ANIMAL EXPERIMENT; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG HALF LIFE; DRUG RETENTION; ISOTOPE LABELING; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RADIOISOTOPE DECAY; VITREOUS BODY; ANIMAL; ANIMAL MODEL; BIOLOGICAL MODEL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST MEDIUM EXTRAVASATION; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING; THYROID GLAND; TISSUE DISTRIBUTION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; INTRAVITREAL INJECTIONS; IODINE RADIOISOTOPES; MALE; MODELS, ANIMAL; MODELS, BIOLOGICAL; POSITRON-EMISSION TOMOGRAPHY; RABBITS; THYROID GLAND; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED; VITREOUS BODY;

EID: 80053300764     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6862     Document Type: Article

References (17)

1. Rosenfeld PJ, Brown DM Heier JS, et al. for the MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355:1419-1431.
2. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
3. Boyer DS, Heier JS, Brown DM, et al. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009;116:1731-1739.
4. Ueta T, Yanagi Y, Tamaki Y, Yamaguchi T. Ranibizumab and stroke. Ophthalmology. 2010;117:1860.
5. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol. 2011;56:95-113.
6. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;359:427-434.
7. Shah MA, Ilson D, Kelsen DP. Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan-and bevacizumab-based therapy. J Clin Oncol. 2005;23:2574-2576.
8. Lordick F, Neinitz H, Thelsen J, Sendler A, Sarbia M. Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys. 2006;64:1295-1298.
9. Gordon CR, Rojavin Y, Patel M, et al. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg. 2009;62:707-709.
10. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114: 855-859.
11. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179-2182.
12. Kim H, Csaky KG, Chan CC et al. The pharmacokinetics of rituximab following an intravitreal injection. Exp Eye Res. 2006;82: 760-762.
13. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46:726-733.
14. H2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results. World J Surg Oncol. 2010;8:65.
15. Alexa Klettner, Johann Roider. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci. 2008;49:4523-4527.
16. Zhu Q, Ziemssen F, Henke-Fahle S, et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-α in patients with choroidal neovascularization. Ophthalmology. 2008;115:1750-1755.
17. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthlamol. 2008;146:508-512.